Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN.
Journal
Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440
Informations de publication
Date de publication:
25 Nov 2022
25 Nov 2022
Historique:
entrez:
23
11
2022
pubmed:
24
11
2022
medline:
24
11
2022
Statut:
ppublish
Résumé
Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and waning immunity call for next-generation vaccine strategies. Here, we assessed the immunogenicity and protective efficacy of two SARS-CoV-2 vaccines targeting the WA1/2020 spike protein, Ad26.COV2.S (Ad26) and Spike ferritin Nanoparticle (SpFN), in nonhuman primates, delivered as either a homologous (SpFN/SpFN and Ad26/Ad26) or heterologous (Ad26/SpFN) prime-boost regimen. The Ad26/SpFN regimen elicited the highest CD4 T cell and memory B cell responses, the SpFN/SpFN regimen generated the highest binding and neutralizing antibody responses, and the Ad26/Ad26 regimen generated the most robust CD8 T cell responses. Despite these differences, protective efficacy against SARS-CoV-2 Omicron BA.1 challenge was similar for all three regimens. After challenge, all vaccinated monkeys showed significantly reduced peak and day 4 viral loads in both bronchoalveolar lavage and nasal swabs as compared with sham animals. The efficacy conferred by these three immunologically distinct vaccine regimens suggests that both humoral and cellular immunity contribute to protection against SARS-CoV-2 Omicron challenge.
Identifiants
pubmed: 36417525
doi: 10.1126/sciadv.ade4433
pmc: PMC9683731
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
eade4433Références
N Engl J Med. 2021 Sep 2;385(10):951-953
pubmed: 34260834
NPJ Vaccines. 2021 Dec 13;6(1):151
pubmed: 34903722
NPJ Vaccines. 2021 Oct 28;6(1):129
pubmed: 34711815
Sci Transl Med. 2022 Apr 20;14(641):eabn6150
pubmed: 35258323
N Engl J Med. 2021 Nov 18;385(21):2010-2012
pubmed: 34648703
Science. 2020 May 29;368(6494):948-950
pubmed: 32393526
Vaccine. 2008 Jul 4;26(29-30):3626-33
pubmed: 18538900
Toxins (Basel). 2016 Apr 11;8(4):103
pubmed: 27077883
Vaccine. 2015 Oct 13;33(42):5578-5587
pubmed: 26372857
Vaccine. 2010 Apr 9;28(17):2999-3007
pubmed: 20170767
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Sci Transl Med. 2022 Feb 16;14(632):eabi5735
pubmed: 34914540
Front Immunol. 2018 Oct 04;9:2224
pubmed: 30337923
JAMA. 2021 Apr 20;325(15):1535-1544
pubmed: 33704352
J Virol. 2021 Nov 9;95(23):e0097421
pubmed: 34523968
Curr Opin Immunol. 2009 Jun;21(3):346-51
pubmed: 19500964
J Immunol Methods. 2011 Mar 7;366(1-2):8-19
pubmed: 21192942
Cell Rep. 2021 Dec 21;37(12):110143
pubmed: 34919799
Biochim Biophys Acta. 2015 Mar;1848(3):775-80
pubmed: 25511587
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Nat Med. 2021 Aug;27(8):1379-1384
pubmed: 34127854
Curr Opin Immunol. 1999 Apr;11(2):172-9
pubmed: 10322151
Nat Rev Immunol. 2021 Jun;21(6):340-341
pubmed: 33927376
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
Nature. 2022 Mar;603(7901):493-496
pubmed: 35102312
Curr Opin HIV AIDS. 2010 Sep;5(5):428-34
pubmed: 20978385
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
J Virol. 2021 Mar 10;:
pubmed: 33692201
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
Nature. 2022 Jan;601(7892):177
pubmed: 34987210
Lancet Infect Dis. 2022 Jan;22(1):110-122
pubmed: 34529962
J Virol. 2021 Jan 20;:
pubmed: 33472939
Nat Rev Immunol. 2010 Nov;10(11):787-96
pubmed: 20948547
J Immunol Methods. 2019 Oct;473:112630
pubmed: 31301278
Nat Rev Microbiol. 2022 May;20(5):251-252
pubmed: 35288685
J Virol. 2021 Mar 16;:
pubmed: 33727331